Inclusion Criteria:  Body mass index (BMI) >=18.0 and <=30.0 kg/m^2. Healthy as determined by medical history and physical examination. Nonsmoker Normal clinical laboratory test results and ECG, or results with minor deviations which are not considered to be clinically significant in the judgment of the investigator. Men of and women of childbearing potential to follow protocol defined contraception methods. Women must have negative urine pregnancy test. Willingness and ability to swallow study drug capsules.  Exclusion Criteria:  Prior or ongoing clinically significant illness, medical condition, medical history, physical findings, ECG findings, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the subject; alter the absorption, distribution, metabolism, or excretion of the study drug; or impair the assessment of study results. Evidence of ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections). Women cannot be pregnant or breast feeding. Significant history of drug or alcohol abuse or addiction within 3 years before study screening or as evidenced by continuing medical complications of prior drug or alcohol use. History of blood or plasma donation within 90 days before first study drug administration. Currently drinking over 21 units/week of ethanol Drug toxicology screen positive for any prohibited drugs, illicit substances, or alcohol. Anticipated need for alcohol, tobacco, or any drug during the study drug administration and immediate follow-up periods. Relative to admission has any of the following exposures: has taken a prescription systemic medication within 14 days; has used an over-the counter systemic medication (other than acetaminophen) within 7 days; has ingested calcium supplements or calcium-containing vitamins within 7 days; has ingested grapefruit, grapefruit juice, or grapefruit-containing products within 7 days; has consumed alcohol within 48 hours; has taken acetaminophen within 24 hours. Positive test for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen or hepatitis B core antibody, or hepatitis C antibody. Unwillingness to avoid vigorous physical activity during inpatient clinic confinements. Part 2 only - Inability or unwillingness to eat all of the ingredients of the high-fat, high-calorie meal as specified in the protocol. Part 3 only - Known allergy to itraconazole or other azole compounds.